Moderna Files for Canada Authorization of Covid-19 Vaccine in Children 6-11 Years
November 17 2021 - 9:09AM
Dow Jones News
By Michael Dabaie
Moderna Inc. said it filed for authorization of its Covid-19
vaccine with Health Canada to include children ages 6 to 11.
The biotechnology company said it submitted for authorization
with Health Canada for the evaluation of a 50 microgram two-dose
series of Spikevax in children ages 6 to 11 years.
Moderna earlier this month filed to expand the conditional
marketing authorization for its Covid-19 vaccine in the European
Union to include children aged 6 to 11.
The Phase 2/3 KidCOVE study of the vaccine in pediatric
population ages 6 months to under 12 years is continuing. Moderna
recently shared data from the KidCOVE study in children 6 years to
11. Vaccine efficacy of 100% using the Phase 3 COVE study primary
case definition for Covid-19 was observed two weeks after the first
dose of Spikevax at the 50 ug dose level, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 17, 2021 08:54 ET (13:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024